Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Matthew P. Goetz; William J. Gradishar; Benjamin O. Anderson; Jame Abraham; Rebecca Aft; Kimberly H. Allison; Sarah L. Blair; Harold J. Burstein; Chau Dang; Anthony D. Elias; William B. Farrar; Sharon H. Giordano; Lori J. Goldstein; Steven J. Isakoff; Janice Lyons; P. Kelly Marcom; Ingrid A. Mayer; Meena S. Moran; Joanne Mortimer; Ruth M. O’Regan; Sameer A. Patel; Lori J. Pierce; Elizabeth C. Reed; Hope S. Rugo; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; Melinda L. Telli; John H. Ward; Jessica S. Young; Dorothy A. Shead; Rashmi Kumar

doi:10.6004/jnccn.2019.0009

Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Matthew P. Goetz
, William J. Gradishar
, Benjamin O. Anderson
, Jame Abraham
, Rebecca Aft
, Kimberly H. Allison
, Sarah L. Blair
, Harold J. Burstein
, Chau Dang
, Anthony D. Elias
, William B. Farrar
, Sharon H. Giordano
, Lori J. Goldstein
, Steven J. Isakoff
, Janice Lyons
, P. Kelly Marcom
, Ingrid A. Mayer
, Meena S. Moran
, Joanne Mortimer
, Ruth M. O’Regan

Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica S. Young, Dorothy A. Shead, Rashmi Kumar

Surgery

Research output: Contribution to journal › Article › peer-review

172 Scopus citations

Abstract

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Original language	English
Pages (from-to)	118-126
Number of pages	9
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	17
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2019.0009
State	Published - Feb 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2019.0009

Cite this

Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Farrar, W. B., Giordano, S. H., Goldstein, L. J., Isakoff, S. J., Lyons, J., Kelly Marcom, P., Mayer, I. A., Moran, M. S., Mortimer, J., ... Kumar, R. (2019). Breast cancer, version 3.2018 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 17(2), 118-126. https://doi.org/10.6004/jnccn.2019.0009

@article{43287c9ee84246628420c71233edca60,

title = "Breast cancer, version 3.2018 featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.",

author = "Goetz, \{Matthew P.\} and Gradishar, \{William J.\} and Anderson, \{Benjamin O.\} and Jame Abraham and Rebecca Aft and Allison, \{Kimberly H.\} and Blair, \{Sarah L.\} and Burstein, \{Harold J.\} and Chau Dang and Elias, \{Anthony D.\} and Farrar, \{William B.\} and Giordano, \{Sharon H.\} and Goldstein, \{Lori J.\} and Isakoff, \{Steven J.\} and Janice Lyons and \{Kelly Marcom\}, P. and Mayer, \{Ingrid A.\} and Moran, \{Meena S.\} and Joanne Mortimer and O{\textquoteright}Regan, \{Ruth M.\} and Patel, \{Sameer A.\} and Pierce, \{Lori J.\} and Reed, \{Elizabeth C.\} and Rugo, \{Hope S.\} and Amy Sitapati and Smith, \{Karen Lisa\} and Smith, \{Mary Lou\} and Hatem Soliman and Telli, \{Melinda L.\} and Ward, \{John H.\} and Young, \{Jessica S.\} and Shead, \{Dorothy A.\} and Rashmi Kumar",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2019",

month = feb,

doi = "10.6004/jnccn.2019.0009",

language = "English",

volume = "17",

pages = "118--126",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "2",

}

Goetz, MP, Gradishar, WJ, Anderson, BO, Abraham, J, Aft, R, Allison, KH, Blair, SL, Burstein, HJ, Dang, C, Elias, AD, Farrar, WB, Giordano, SH, Goldstein, LJ, Isakoff, SJ, Lyons, J, Kelly Marcom, P, Mayer, IA, Moran, MS, Mortimer, J, O’Regan, RM, Patel, SA, Pierce, LJ, Reed, EC, Rugo, HS, Sitapati, A, Smith, KL, Smith, ML, Soliman, H, Telli, ML, Ward, JH, Young, JS, Shead, DA & Kumar, R 2019, 'Breast cancer, version 3.2018 featured updates to the NCCN guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 17, no. 2, pp. 118-126. https://doi.org/10.6004/jnccn.2019.0009

TY - JOUR

T1 - Breast cancer, version 3.2018 featured updates to the NCCN guidelines

AU - Goetz, Matthew P.

AU - Gradishar, William J.

AU - Anderson, Benjamin O.

AU - Abraham, Jame

AU - Aft, Rebecca

AU - Allison, Kimberly H.

AU - Blair, Sarah L.

AU - Burstein, Harold J.

AU - Dang, Chau

AU - Elias, Anthony D.

AU - Farrar, William B.

AU - Giordano, Sharon H.

AU - Goldstein, Lori J.

AU - Isakoff, Steven J.

AU - Lyons, Janice

AU - Kelly Marcom, P.

AU - Mayer, Ingrid A.

AU - Moran, Meena S.

AU - Mortimer, Joanne

AU - O’Regan, Ruth M.

AU - Patel, Sameer A.

AU - Pierce, Lori J.

AU - Reed, Elizabeth C.

AU - Rugo, Hope S.

AU - Sitapati, Amy

AU - Smith, Karen Lisa

AU - Smith, Mary Lou

AU - Soliman, Hatem

AU - Telli, Melinda L.

AU - Ward, John H.

AU - Young, Jessica S.

AU - Shead, Dorothy A.

AU - Kumar, Rashmi

PY - 2019/2

Y1 - 2019/2

N2 - These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

AB - These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

UR - https://www.scopus.com/pages/publications/85061964738

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000459172500005&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2019.0009

DO - 10.6004/jnccn.2019.0009

M3 - Article

C2 - 30787125

SN - 1540-1405

VL - 17

SP - 118

EP - 126

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 2

ER -

Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this